

EXHIBIT 5



STANFORD UNIVERSITY
OFFICE OF TECHNOLOGY LICENSING
FACSIMILE COVER SHEET

FAXED
5/4/04

DATE: May 4, 2004
~~6/2/2005~~

TO: Bill Gaede, Esq.
Cooley Godward

FROM: Luis Mejia, Senior Associate
Stanford University
1705 El Camino Real
Palo Alto, CA 94306
Fax Number: 650-725-7295
Phone: 650-723-0651
mejia@stanford.edu

Copy: 650-~~845-546~~ 857-0663

Patrick Dunkley, Esq. e-mail:

TOTAL NUMBER OF PAGES: 5 including cover sheet.
If you experience problems please call 650-723-0651 immediately.

Re: Roche Matter (Stanford Docket - 598-058)

**DEPOSITION
EXHIBIT** LM
612
gen 8/15/02

STAN 010298
CONFIDENTIAL -
ATTORNEYS' EYES ONLY

George C. Jen, Ph.D., J.D.
Senior Patent Counsel
Dir. Dial: 510 814-2966
Facsimile: 510 814-2973
george.jen@roche.com



Diagnosics

May 3, 2004

Via Courier

Mr. Luis R. Mejia
Stanford University
Office of Technology Licensing
1705 El Camino Real
Palo Alto, CA 94306

Re: US Patent No. 6,503,705 (Stanford Docket S98-058)

Dear Mr. Mejia:

Thank you for the letter dated April 9, 2004 in connection with this patent.


Regarding our inventorship concerns, it is appropriate to inform you at this time only that we have interviewed Cetus scientists who interacted with Dr. Merigan during the late 80 to early 90s period when he collaborated with Cetus and served as consultant in HIV testing. Those interviews indicate Cetus scientists provided Dr. Merigan with ideas and information relating to PCR-based HIV testing that led to or formed the basis of the claimed invention of this patent.

We wish to further point out that on April 27, 1991 Dr. Merigan executed a consulting agreement that grants Cetus ownership to certain inventions he "discovered, created, made, conceived or reduced to practice" within two years of that date. See paragraph 5 of the attached agreement. We note that the '705 patent, as do other family members, claims priority of an application filed on May 14, 1992. Thus, in addition to ownership rights RMS may have by virtue of the 1988 MTA and joint inventorship by Cetus scientists, we have an additional claim to this patent and family members based on this agreement.

Lastly, the consulting agreement requires Dr. Merigan to report such inventions to Cetus. We have no record of Dr. Merigan complying with this obligation.

Our prior settlement offer concerning this patent family remains open. We hope Stanford will give it serious consideration.

Very truly yours,


George C. Jen

Enclosure

cc: Melinda Griffith, Esq. (w/o enclosure)

NON-EXCLUSIVE CONSULTING AGREEMENT

RECEIVED

MAY 1 1991

THIS AGREEMENT is effective as of April 19, 1991, by and between Cetus Corporation ("Cetus"), and Thomas C. Merigan, M.D. ("Consultant").

*S/10/91
gmc*

1. **Consultancy.** Cetus hereby retains Consultant, and Consultant hereby accepts such retention, commencing as of the date of this Agreement and continuing for one (1) year thereafter.

2. **Services.** Consultant shall serve as a scientific consultant to Cetus and its subsidiaries and affiliates in the research and development of therapeutic agents (the "Field").

3. **Compensation.** Cetus will pay Consultant a retainer fee of \$6,000, plus a consulting fee of \$1,500 per day for services requested and performed. Payments will be made upon receipt of an invoice detailing the services rendered by Consultant pursuant to this Agreement. Cetus will reimburse Consultant for reasonable expenses approved in advance by Cetus.

4. **Outside Employment.** (a) During the term of this Agreement Consultant may be engaged by one or more other "Institution(s)." Consultant represents that he is not and shall not become a party to any agreement which conflicts with the duties hereunder. Consultant shall use best efforts to segregate work done under this Agreement from work at an Institution, or done with Government funding, so as to minimize any questions of disclosure or ownership of rights under any Inventions or Confidential Information. Cetus may terminate this Agreement if in its sole opinion the performance of such work will conflict with its interests.

(b) Consultant shall not disclose to Cetus any inventions, trade secrets, or other information of third parties that Consultant does not have the right to disclose and that Cetus is not free to use without liability.

5. **Inventions.** (a) "Invention" shall mean and refer to any composition of matter, device, process, treatment, or improvement thereof discovered, created, made, conceived, or reduced to practice ("Invented") by Consultant, whether patentable or not, during the term of this Agreement or within one year after termination and which: (i) was Invented with the equipment, supplies, facilities, or Confidential Information of Cetus or those acting on its behalf, or (ii) was Invented by Consultant while performing services for Cetus, or (iii) resulted from any work performed by Consultant for Cetus under this Agreement.

(b) Cetus shall own all right, title and interest in any Invention. Consultant shall promptly, and without royalty but at Cetus' expense: (i) disclose to Cetus all information with respect to any Inventions, (ii) execute all applications, assignments, and other instruments and do such other acts that Cetus may deem necessary to obtain and maintain patents, copyrights, and similar rights anywhere in the world, and (iii) provide Cetus evidence needed in any legal proceedings regarding the Invention.

6. Confidentiality. (a) As used in this Agreement, "Confidential Information" shall mean all data, technical information, commercial and research strategies, trade secrets, and know-how disclosed by Cetus to Consultant, directly or indirectly, whether in writing or orally except for such information and know-how that (i) can be shown by contemporaneous documentation to have been in Consultant's possession prior to disclosure by Cetus; (ii) at the time of disclosure hereunder is, or thereafter becomes, through no fault of Consultant, part of the public domain; or (iii) is furnished to Consultant by a third party after the time of disclosure hereunder without the breach of any duty to Cetus.

(b) Consultant shall not use any Confidential Information except for the purposes of this Agreement unless Cetus shall otherwise agree in writing. Consultant may disclose Confidential Information only to employees or agents who have a need to know the Confidential Information for the purposes of this Agreement and who are bound in writing to maintain the secrecy of the Confidential Information and assign to Cetus any Inventions which they may make.

(c) Consultant shall keep separate and segregated from other work all documents, records, notebooks, correspondence, deposits of microorganisms, cells or parts thereof, cell lines, parts and progeny thereof, and all products made thereby, arising from the work under this Agreement. All right, title, and interest therein shall belong to Cetus, and upon expiration or termination of this Agreement, all such documents and material, including copies thereof, whether prepared by Consultant or others, will be delivered to Cetus.

(d) Consultant may lecture upon, disseminate, and publish under Consultant's own name scientific papers arising from the work done in the course of performance of services for Cetus hereunder, but only upon the prior written approval of Cetus. Cetus will not unreasonably withhold its approval provided Confidential Information will not be disclosed thereby. Appropriate credit will be given to Cetus in any publication.

7. Notice. Any notice to Cetus shall be addressed as follows or as shall be specified by a party in writing:

If to Cetus:
Cetus Corporation
1400 Fifty-Third Street
Emeryville, California 94608
Attention: Senior Vice President,
Legal & Corporate Development, and
General Counsel

If to Consultant:
Dr. Thomas C. Merigan
148 Goya Road
Portola Valley, California 94025

8. Survival and Termination. The terms and obligations of paragraphs 5 and 6 shall survive termination of this Agreement for any reason whatsoever. If Consultant breaches any term of this Agreement Cetus may, in addition to any other remedy, terminate Consultant's services immediately by notice to Consultant by letter, facsimile, telephone call, in person, or other reasonable means by any officer or agent of Cetus.

9. **Entire Agreement.** This Agreement is the entire agreement of the parties relating to the subject matter hereof, and supersedes all prior and contemporaneous negotiations, correspondence, understandings, and agreements of the parties relating to the subject matter hereof. It may be amended only by an agreement in writing, signed by both parties.

10. **Not an Employee.** Consultant is an independent contractor and is not an employee or agent of Cetus. Consultant shall be entitled to no benefits or compensation from Cetus except as set forth in this Agreement and shall in no event be entitled to any fringe benefits payable to employees of Cetus.

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

CETUS CORPORATION

THOMAS C. MERIGAN, M.D. Inc.

By:

James H. Meade
James H. Meade, Ph.D.
Senior Director
Scientific Administration
4/25/91
Date

Thomas C. Merigan
94-3008940
Social Security Number Employee Identificat Number
4/27/91
Date

JB/MDM/JHM/GHE:ghe
merigan.csa

** N.B. My zip code is now
94028*